ZYBT Stock Analysis: Zhengye Biotechnology Holding Limited
One-sentence summary of key findings: Zhengye Biotechnology Holding Limited (ZYBT) is a small Chinese veterinary vaccine manufacturer that completed a NASDAQ IPO in January 2025, with operations showing sharply declining revenues and a shift to significant net losses in recent fiscal years amid high stock volatility and Nasdaq compliance issues.
Stock Performance and Company Financials
Links for more information: Yahoo Finance Quote & History | Yahoo Key Statistics | Yahoo Financials | StockTitan Overview
Stock Performance Overview (Facts from Market Data)
- 52-week trading range: $0.6160 (low) to $13.0800 (high).[[1]](https://finance.yahoo.com/quote/ZYBT/)[[2]](https://finance.yahoo.com/quote/ZYBT/key-statistics/)
- 52-week change: approximately -76.63% (as of data around early August 2026).[[2]](https://finance.yahoo.com/quote/ZYBT/key-statistics/)
- Post-IPO volatility noted with events including trading halts and unusual activity in July 2026.[[3]](https://www.cnn.com/markets/stocks/ZYBT)
- Average volume (3-month): ~3.98 million shares; recent periods showed spikes (e.g., 10-day avg ~6.77M).[[2]](https://finance.yahoo.com/quote/ZYBT/key-statistics/)
Interpretation: The wide price range and negative 52-week performance reflect significant post-IPO volatility typical of micro-cap biotechs, potentially driven by low float (~6.26M shares) and market sentiment around the company's financial trajectory.
Uncertainty: Exact performance metrics can vary by exact date and data source; no long-term historical data available pre-IPO.
Company Financials (Facts; Currency Primarily in CNY with USD Equivalents Noted Where Available)
Data Limitation: Financials sourced from Yahoo Finance (TTM as of latest available ~2025/2026 data); fiscal year ends December 31; some figures in CNY (e.g., income statement) converted/contextualized to USD in other summaries; revenue figures show consistent downward trend across sources. Chinese reporting standards and currency fluctuations add uncertainty. No forward guidance or analyst estimates publicly detailed.
Income Statement Highlights (in CNY millions, approx. USD context from sources)
| Metric | 2022 | 2023 | 2024 | 2025 / TTM |
|---|
| Total Revenue | 260.27M | 211.65M | 186.36M | 116.36M (~$16M USD equiv. in some reports) |
| Gross Profit | 147.88M | 117.51M | 91.3M | 23.87M |
| Operating Income | 66.09M | 47.64M | 17.17M | -68.25M |
| Net Income | 46.74M | 31.46M | 11.31M | -69.78M (~ -60% margin) |
| Diluted EPS | 0.99 | 0.67 | 0.24 | -1.47 or -0.22 (USD equiv.) |
Quarterly revenue growth (yoy): -40.90%.[[2]](https://finance.yahoo.com/quote/ZYBT/key-statistics/)
Key Balance Sheet & Profitability Metrics (USD where specified)
| Metric | Value (TTM / mrq) |
|---|
| Revenue (TTM) | $116.36M |
| Net Income (TTM) | -$69.78M |
| Profit Margin | -59.97% |
| Operating Margin (TTM) | -77.04% |
| Return on Assets (TTM) | -9.48% |
| Return on Equity (TTM) | -25.17% |
| Total Cash (mrq) | $51.89M |
| Total Debt (mrq) | $75.08M |
| Debt/Equity (mrq) | 24.48% |
| Book Value Per Share (mrq) | $0.78 |
Interpretation: Sharp revenue decline (from profitable operations pre-2025 to losses) and negative margins suggest operational challenges, possibly from market conditions in China's livestock vaccine sector or increased competition/expenses post-IPO.
Employees: 269 (as of latest data).[[1]](https://finance.yahoo.com/quote/ZYBT/)
Analyst Ratings
Links for more information: Yahoo Finance (1y Target Est: --) | Investing.com Consensus | WSJ Research Ratings
- No specific analyst ratings, price targets, or consensus estimates publicly available (e.g., Yahoo shows "--" for 1y Target Est; limited or no coverage noted across sources).[[1]](https://finance.yahoo.com/quote/ZYBT/)[[4]](https://www.investing.com/equities/zhengye-biotechnology-holding)
- One source describes potential performance as "neutral in line with market averages" over next 12 months (pre-dating recent volatility).[[3]](https://www.cnn.com/markets/stocks/ZYBT)
Interpretation: Lack of coverage is common for recent micro-cap IPOs; investors rely primarily on company disclosures.
Uncertainty: Future analyst initiation possible but not indicated; ratings can change rapidly with new data.
Data Limitation: As a recently listed company (IPO Jan 2025), institutional analyst coverage is minimal or absent in available sources.
Customers and Competitors
Links for more information: Yahoo Company Profile | MarketBeat Competitors | AAII Peer Comparison
Customers (Facts)
- Direct end-customers: livestock farmers and local governments in China.[[1]](https://finance.yahoo.com/quote/ZYBT/)
- Distribution channels: domestic distributors and exporting distributors.[[1]](https://finance.yahoo.com/quote/ZYBT/)
- Export markets: Vietnam, Pakistan, and Egypt (veterinary vaccines).[[1]](https://finance.yahoo.com/quote/ZYBT/)[[5]](https://www.jlzybio.com)
- Primary revenue driver: swine vaccines, followed by poultry and others.[[6]](https://www.morningstar.com/stocks/xnas/zybt/quote)
Interpretation: Heavy reliance on Chinese domestic livestock sector (esp. swine) exposes the company to agricultural cycles, disease outbreaks, and local regulations.
Competitors (Facts & Comparisons)
Direct animal health/veterinary vaccine competitors are limited in public data; broader peers in specialty/generic drug manufacturers or small-cap biotechs include:
| Company | Ticker | Notes |
|---|
| Phibro Animal Health | PAHC | Larger animal health player (market cap ~$1.48B); more established.[[1]](https://finance.yahoo.com/quote/ZYBT/) |
| China Pharma Holdings | CPHI | Small Chinese pharma peer (~$48M cap).[[1]](https://finance.yahoo.com/quote/ZYBT/) |
| Sol-Gel Technologies | SLGL | Biotech peer (often compared).[[7]](https://www.marketbeat.com/stocks/NASDAQ/ZYBT/competitors-and-alternatives/) |
| AC Immune | ACIU | Biotech peer.[[7]](https://www.marketbeat.com/stocks/NASDAQ/ZYBT/competitors-and-alternatives/) |
| Context Therapeutics / BioStem Technologies / Cingulate | CNTX / BSEM / CING | Similar small-cap pharma peers (~$58-68M caps).[[8]](https://www.aaii.com/investingideas/article/247922-is-zhengye-biotechnology-holding-limited-zybt-stock-a-good-investment) |
Interpretation: ZYBT operates in a niche (Chinese veterinary vaccines) with fewer direct listed competitors; larger global players like Phibro or Teva (TEVA) dominate broader segments.
Uncertainty: Competitive landscape in China's domestic market may include unlisted state or private firms not captured in public data.
Company Overview & History (Additional Context)
Links: Official Website (Chinese/English elements) | Yahoo Profile
- Core business: R&D, manufacturing, and sales of ~44 veterinary vaccines (monovalent, polyvalent, combined) for swine, poultry, cattle, goats, sheep, dogs; also pet vaccines (e.g., rabies). 14 GMP production lines; animal testing center.[[1]](https://finance.yahoo.com/quote/ZYBT/)[[5]](https://www.jlzybio.com)
- History: Roots trace to 1970 relocation of Harbin Veterinary Biopharma Plant to Jilin City; restructured 2004 from provincial state-owned to private joint-stock company (Jilin Zhengye Biological Products Co., Ltd.). NASDAQ IPO January 7, 2025 (first in China's animal health sector); operates as subsidiary of Securingium Holding Limited.[[5]](https://www.jlzybio.com)[[1]](https://finance.yahoo.com/quote/ZYBT/)
- Recognitions: National high-tech enterprise; provincial engineering centers; export demonstration enterprise (2020); multiple Jilin provincial honors.[[5]](https://www.jlzybio.com)
Interpretation: Long operational history in vaccines provides technical expertise, but transition to public company and recent financial pressures indicate execution risks.
Recent News Highlights
Links: Yahoo News | GlobeNewswire (company releases)
- July 2026: Comments on unusual Nasdaq trading activity; trading halted then resumed.[[3]](https://www.cnn.com/markets/stocks/ZYBT)
- June 2026: Nasdaq notification on minimum bid price deficiency.[[3]](https://www.cnn.com/markets/stocks/ZYBT)
- April 2026: Implementation of dual-class share structure.[[3]](https://www.cnn.com/markets/stocks/ZYBT)
- Earlier: FY2024 results (July 2025 release); IPO closing/over-allotment (Jan 2025); Chairman's letter (Feb 2026).[[3]](https://www.cnn.com/markets/stocks/ZYBT)
Overall Data Limitations & Assumptions: All information derived from publicly available web sources as of ~August 2026 crawls; financials and performance are historical and subject to restatement or revision. No real-time data or proprietary forecasts included. Micro-cap Chinese NASDAQ listings carry additional risks (e.g., regulatory scrutiny, currency, geopolitical) not quantified here. Always verify latest SEC filings (e.g., 20-F) and consult professionals. Stock data excludes any current price per guidelines.